vs
Envoy Medical, Inc.（COCH）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Sanara MedTech Inc.的季度营收约是Envoy Medical, Inc.的366.9倍（$27.5M vs $75.0K）。Sanara MedTech Inc.净利率更高（-5.9% vs -8781.3%，领先8775.5%）。Envoy Medical, Inc.同比增速更快（78.6% vs 4.6%）。Sanara MedTech Inc.自由现金流更多（$3.9M vs $-5.9M）。过去两年Sanara MedTech Inc.的营收复合增速更高（21.8% vs 12.7%）
Envoy Medical是一家专注于植入式听力解决方案研发和商业化的医疗科技企业，核心产品为全植入式中耳听力设备，主要服务于使用常规外置助听器效果不佳的感音神经性听力损失患者，市场覆盖北美、欧洲等地区。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
COCH vs SMTI — 直观对比
营收规模更大
SMTI
是对方的366.9倍
$75.0K
营收增速更快
COCH
高出74.0%
4.6%
净利率更高
SMTI
高出8775.5%
-8781.3%
自由现金流更多
SMTI
多$9.7M
$-5.9M
两年增速更快
SMTI
近两年复合增速
12.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $75.0K | $27.5M |
| 净利润 | $-6.6M | $-1.6M |
| 毛利率 | -181.3% | 93.2% |
| 营业利润率 | -8513.3% | 23.5% |
| 净利率 | -8781.3% | -5.9% |
| 营收同比 | 78.6% | 4.6% |
| 净利润同比 | -42.6% | 5.3% |
| 每股收益（稀释后） | $-0.27 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COCHSMTI
| Q4 25 | $75.0K | $27.5M | ||
| Q3 25 | $42.0K | $26.3M | ||
| Q2 25 | $78.0K | $25.8M | ||
| Q1 25 | $46.0K | $23.4M | ||
| Q4 24 | $42.0K | $26.3M | ||
| Q3 24 | $56.0K | $21.7M | ||
| Q2 24 | $68.0K | $20.2M | ||
| Q1 24 | $59.0K | $18.5M |
净利润COCHSMTI
| Q4 25 | $-6.6M | $-1.6M | ||
| Q3 25 | $-6.5M | $-30.4M | ||
| Q2 25 | $-5.7M | $-2.0M | ||
| Q1 25 | $-5.0M | $-3.5M | ||
| Q4 24 | $-4.6M | $-1.7M | ||
| Q3 24 | $-6.0M | $-2.9M | ||
| Q2 24 | $-3.9M | $-3.5M | ||
| Q1 24 | $-6.3M | $-1.8M |
毛利率COCHSMTI
| Q4 25 | -181.3% | 93.2% | ||
| Q3 25 | -383.3% | 92.9% | ||
| Q2 25 | -200.0% | 92.5% | ||
| Q1 25 | -391.3% | 92.2% | ||
| Q4 24 | -273.8% | 91.4% | ||
| Q3 24 | -233.9% | 90.8% | ||
| Q2 24 | -260.3% | 90.0% | ||
| Q1 24 | -159.3% | 89.8% |
营业利润率COCHSMTI
| Q4 25 | -8513.3% | 23.5% | ||
| Q3 25 | -13590.5% | 11.2% | ||
| Q2 25 | -6500.0% | -0.1% | ||
| Q1 25 | -11102.2% | -8.9% | ||
| Q4 24 | -10828.6% | 18.6% | ||
| Q3 24 | -8878.6% | 3.6% | ||
| Q2 24 | -7135.3% | -14.3% | ||
| Q1 24 | -8278.0% | -8.3% |
净利率COCHSMTI
| Q4 25 | -8781.3% | -5.9% | ||
| Q3 25 | -15433.3% | -115.5% | ||
| Q2 25 | -7294.9% | -7.8% | ||
| Q1 25 | -10865.2% | -15.1% | ||
| Q4 24 | -10995.2% | -6.5% | ||
| Q3 24 | -10642.9% | -13.2% | ||
| Q2 24 | -5804.4% | -17.4% | ||
| Q1 24 | -10627.1% | -9.5% |
每股收益（稀释后）COCHSMTI
| Q4 25 | $-0.27 | $-0.32 | ||
| Q3 25 | $-0.35 | $-3.40 | ||
| Q2 25 | $-0.32 | $-0.23 | ||
| Q1 25 | $-0.29 | $-0.41 | ||
| Q4 24 | $-0.40 | $-0.18 | ||
| Q3 24 | $-0.39 | $-0.34 | ||
| Q2 24 | $-0.29 | $-0.41 | ||
| Q1 24 | $-0.41 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $16.6M |
| 总债务越低越好 | — | $46.0M |
| 股东权益账面价值 | $-12.2M | $5.9M |
| 总资产 | $8.6M | $72.9M |
| 负债/权益比越低杠杆越低 | — | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资COCHSMTI
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
总债务COCHSMTI
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
股东权益COCHSMTI
| Q4 25 | $-12.2M | $5.9M | ||
| Q3 25 | $-7.7M | $6.1M | ||
| Q2 25 | $-29.9M | $35.4M | ||
| Q1 25 | $-24.2M | $36.7M | ||
| Q4 24 | $-18.8M | $39.4M | ||
| Q3 24 | $-18.5M | $39.8M | ||
| Q2 24 | $-12.4M | $41.7M | ||
| Q1 24 | $-7.4M | $43.3M |
总资产COCHSMTI
| Q4 25 | $8.6M | $72.9M | ||
| Q3 25 | $8.2M | $71.1M | ||
| Q2 25 | $9.9M | $98.8M | ||
| Q1 25 | $10.4M | $96.4M | ||
| Q4 24 | $11.5M | $88.1M | ||
| Q3 24 | $9.4M | $88.5M | ||
| Q2 24 | $6.7M | $73.4M | ||
| Q1 24 | $8.5M | $70.9M |
负债/权益比COCHSMTI
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $3.9M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $3.9M |
| 自由现金流率自由现金流/营收 | -7809.3% | 14.0% |
| 资本支出强度资本支出/营收 | 229.3% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.2M |
8季度趋势，按日历期对齐
经营现金流COCHSMTI
| Q4 25 | $-5.7M | $3.9M | ||
| Q3 25 | $-4.3M | $2.2M | ||
| Q2 25 | $-4.5M | $2.7M | ||
| Q1 25 | $-3.7M | $-2.0M | ||
| Q4 24 | $-5.1M | $932.0K | ||
| Q3 24 | $-2.6M | $2.1M | ||
| Q2 24 | $-4.6M | $-1.4M | ||
| Q1 24 | $-5.6M | $-1.6M |
自由现金流COCHSMTI
| Q4 25 | $-5.9M | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-4.5M | $902.7K | ||
| Q1 25 | $-3.7M | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | $-3.8M | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | $-5.7M | $-1.7M |
自由现金流率COCHSMTI
| Q4 25 | -7809.3% | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | -5719.2% | 3.5% | ||
| Q1 25 | -8110.9% | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -6750.0% | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | -9657.6% | -9.0% |
资本支出强度COCHSMTI
| Q4 25 | 229.3% | 0.3% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 1.3% | 6.8% | ||
| Q1 25 | 13.0% | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 2066.1% | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | 184.7% | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COCH
暂无分部数据
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
